INT205480

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 4.11
Pain Relevance 0.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Egfr, Stat3) nucleus (Egfr, Stat3) signal transducer activity (Egfr, Stat3)
cytoplasm (Egfr, Stat3) cell proliferation (Egfr, Stat3) signal transduction (Egfr, Stat3)
Egfr (Mus musculus)
Stat3 (Mus musculus)
Pain Link Frequency Relevance Heat
aspirin 13 52.96 Quite High
imagery 13 5.00 Very Low Very Low Very Low
cINOD 12 5.00 Very Low Very Low Very Low
Inflammation 9 5.00 Very Low Very Low Very Low
tolerance 2 5.00 Very Low Very Low Very Low
ketamine 1 5.00 Very Low Very Low Very Low
depression 1 5.00 Very Low Very Low Very Low
adenocard 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Apoptosis 10 98.52 Very High Very High Very High
Cancer 475 97.40 Very High Very High Very High
Metastasis 85 87.12 High High
Sprains And Strains 148 86.80 High High
Lung Cancer 1 83.76 Quite High
Ovarian Cancer 33 80.88 Quite High
Breast Cancer 53 79.08 Quite High
Skin Cancer 1 62.96 Quite High
Targeted Disruption 16 5.00 Very Low Very Low Very Low
Disease 16 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It is the early phase of tumor formation that is most affected in the absence of iNOS, consistent with recent data linking iNOS expression with transcriptional upregulation of signal transducers and activators of transcription 3 (STAT3) by nuclear epidermal growth factor receptor (EGFR) (Lo et al. 2005).
nuclear epidermal growth factor receptor Positive_regulation (upregulation) of signal transducers and activators of transcription 3 associated with cancer
1) Confidence 0.58 Published 2007 Journal Transgenic Res Section Body Doc Link PMC1829418 Disease Relevance 0.83 Pain Relevance 0
It is the early phase of tumor formation that is most affected in the absence of iNOS, consistent with recent data linking iNOS expression with transcriptional upregulation of signal transducers and activators of transcription 3 (STAT3) by nuclear epidermal growth factor receptor (EGFR) (Lo et al. 2005).
nuclear epidermal growth factor receptor Positive_regulation (upregulation) of STAT3 associated with cancer
2) Confidence 0.58 Published 2007 Journal Transgenic Res Section Body Doc Link PMC1829418 Disease Relevance 0.83 Pain Relevance 0
It is the early phase of tumor formation that is most affected in the absence of iNOS, consistent with recent data linking iNOS expression with transcriptional upregulation of signal transducers and activators of transcription 3 (STAT3) by nuclear epidermal growth factor receptor (EGFR) (Lo et al. 2005).
EGFR Positive_regulation (upregulation) of STAT3 associated with cancer
3) Confidence 0.42 Published 2007 Journal Transgenic Res Section Body Doc Link PMC1829418 Disease Relevance 0.83 Pain Relevance 0
It is the early phase of tumor formation that is most affected in the absence of iNOS, consistent with recent data linking iNOS expression with transcriptional upregulation of signal transducers and activators of transcription 3 (STAT3) by nuclear epidermal growth factor receptor (EGFR) (Lo et al. 2005).
EGFR Positive_regulation (upregulation) of signal transducers and activators of transcription 3 associated with cancer
4) Confidence 0.42 Published 2007 Journal Transgenic Res Section Body Doc Link PMC1829418 Disease Relevance 0.83 Pain Relevance 0
STAT3 can be activated by various protein tyrosine kinases including Janus tyrosine kinases (JAK) and the proto-oncogene tyrosine kinase (Src), as well as membrane-bound growth factor receptor tyrosine kinases such as EGFR [52].
EGFR Positive_regulation (activated) of STAT3
5) Confidence 0.15 Published 2008 Journal J Transl Med Section Body Doc Link PMC2267444 Disease Relevance 0.81 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox